134 related articles for article (PubMed ID: 34612744)
1. Phosphatidylinositol 3-kinase signaling inhibitors for treatment of multiple myeloma: From small molecules to microRNAs.
Mehdizadeh M; Farhadihosseinabadi B; Nikoonezhad M; Sankanian G; Soleimani M; Sayad A
J Oncol Pharm Pract; 2022 Jan; 28(1):149-158. PubMed ID: 34612744
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-21 and multiple myeloma: small molecule and big function.
Ma J; Liu S; Wang Y
Med Oncol; 2014 Aug; 31(8):94. PubMed ID: 24981236
[TBL] [Abstract][Full Text] [Related]
4. Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma.
Zhu J; Wang M; Cao B; Hou T; Mao X
Curr Med Chem; 2014; 21(27):3173-87. PubMed ID: 24934342
[TBL] [Abstract][Full Text] [Related]
5. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
Hu J; Hu WX
Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
[TBL] [Abstract][Full Text] [Related]
6. Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.
Hu Q; Wang M; Wang J; Tao Y; Niu T
Oncol Res; 2024; 32(4):753-768. PubMed ID: 38560563
[TBL] [Abstract][Full Text] [Related]
7. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Younes H; Leleu X; Hatjiharissi E; Moreau AS; Hideshima T; Richardson P; Anderson KC; Ghobrial IM
Clin Cancer Res; 2007 Jul; 13(13):3771-5. PubMed ID: 17606706
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of microRNA‑25‑3p inhibits the proliferation and promotes the apoptosis of multiple myeloma cells via targeting the PTEN/PI3K/AKT signaling pathway.
Zi Y; Zhang Y; Wu Y; Zhang L; Yang R; Huang Y
Int J Mol Med; 2021 Mar; 47(3):. PubMed ID: 33448321
[TBL] [Abstract][Full Text] [Related]
9. Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma.
Allegra A; Ettari R; Innao V; Bitto A
Cells; 2021 Feb; 10(2):. PubMed ID: 33672466
[TBL] [Abstract][Full Text] [Related]
10. miRNAs driving diagnosis, progression, and drug resistance in multiple myeloma.
Elkady MA; Yehia AM; Elsakka EGE; Abulsoud AI; Abdelmaksoud NM; Elshafei A; Elkhawaga SY; Ismail A; Mokhtar MM; El-Mahdy HA; Hegazy M; Elballal MS; Mohammed OA; El-Husseiny HM; Midan HM; El-Dakroury WA; Zewail MB; Abdel Mageed SS; Doghish AS
Pathol Res Pract; 2023 Aug; 248():154704. PubMed ID: 37499518
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
Ramakrishnan V; Kumar S
Leuk Lymphoma; 2018 Nov; 59(11):2524-2534. PubMed ID: 29322846
[TBL] [Abstract][Full Text] [Related]
12. Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
Shen X; Guo Y; Qi J; Shi W; Wu X; Ni H; Ju S
Pathol Oncol Res; 2016 Jul; 22(3):531-9. PubMed ID: 26689580
[TBL] [Abstract][Full Text] [Related]
13. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
15. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
Wang L; Lin N; Li Y
Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
[TBL] [Abstract][Full Text] [Related]
17. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.
He W; Fu Y; Zheng Y; Wang X; Liu B; Zeng J
BMC Cancer; 2021 Feb; 21(1):125. PubMed ID: 33549034
[TBL] [Abstract][Full Text] [Related]
18. A novel signaling pathway associated with Lyn, PI 3-kinase and Akt supports the proliferation of myeloma cells.
Iqbal MS; Tsuyama N; Obata M; Ishikawa H
Biochem Biophys Res Commun; 2010 Feb; 392(3):415-20. PubMed ID: 20079716
[TBL] [Abstract][Full Text] [Related]
19. Downregulated microRNA-135a ameliorates rheumatoid arthritis by inactivation of the phosphatidylinositol 3-kinase/AKT signaling pathway via phosphatidylinositol 3-kinase regulatory subunit 2.
Qu Y; Zhang YP; Wu J; Jie LG; Deng JX; Zhao DB; Yu QH
J Cell Physiol; 2019 Aug; 234(10):17663-17676. PubMed ID: 30912120
[TBL] [Abstract][Full Text] [Related]
20. A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Zhu J; Wang M; Yu Y; Qi H; Han K; Tang J; Zhang Z; Zeng Y; Cao B; Qiao C; Zhang H; Hou T; Mao X
Oncotarget; 2015 Jan; 6(1):185-95. PubMed ID: 25474140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
